Project Report - Triptoprozene-233

Project Report - Triptoprozene-233

Having completed project TTP233C in response to complaints 1653A45, 1658D24, and 1664C41, my team has determined that roughly one in 900 women exhibit some or all of the following side effects following prolonged or repeated exposure to Triptoprozene-233. While the effects described below admittedly affect only a small subset of Ameranth's clients, these side effects are ****, to say the least.

Observed symptoms:

1. Reduced inhibitions. The subjects become more suggestible, and exhibits less "common sense." The subjects adopt and accept the ideas and outlooks they are presented with quickly and completely, sometimes resulting in an altered personality. For example in Experiment 21, Subject 13 agreed to change her legal name to [-redacted-] when asked by her sexual partner, without offering objection.
2. Heightened arousal and sensitivity. Affected subjects exhibit a marked increase in arousal, and more inclined to act upon that arousal. In our most **** case following Experiment 6, subject 22 had to be restrained after nearly 7 hours of uninterrupted masturbation.
3. Subconscious urges. Some subjects claimed to hear voices at times, generally providing lewd commentary on their actions, natures, or surroundings. I theorize that this may be a form of psychosis, or of the mind's rationalization of the previously mentioned personality shifts.
4. Reduction in mental capacity. Prolonged or heavy exposure has been linked to reduced cognitive functionality in all subjects, though this is difficult to measure accurately as the subjects gradually lose interest in further testing. Vocabulary and reasoning ability is certainly impacted, but to what degree? Further study is required.
5. Hormonal shifts. Subjects all exhibit heightened estrogen levels, as well as above average levels of oxytocin, serotonin, and dopamine. This may explain symptom #2 above, as well as #6 below.
6. Tissue growth, weight loss. Many subjects exhibited accelerated growth of fatty tissues focused around the bust and hips. At the same time, some subjects lost weight as their metabolisms became more efficient. Our most **** example, subject 4, lost 72 pounds while under observation. While this may appear to be a "silver lining" to be investigated for cosmetic application, I strongly urge against pursuing this line of research.

The recorded symptoms I've detailed above are dangerous in the ****, affecting the agency and personality of those affected in a way that I've never encountered in my career. I strongly recommend we recall all products containing Triptoprozene-233 from consumer use as soon as possible until we can develop a safe alternative.

Sincerely,

Victor Ryder, PHD

Manager, Research and Development